Matthew T. Bush

A selection of Mr. Bush’s representations include:

• Airgain, a leading provider of embedded antenna technologies used to enable high performance wireless networking across a broad range of home, enterprise, and industrial devices, in general company representation, its initial public offering, strategic acquisitions, and in corporate governance matters
• Apricus Biosciences in follow-on offerings, corporate governance, and in its reverse merger with Seelos Therapeutics
• Avidity Biosciences in its initial public offering and public company and corporate governance matters 
• Ballast Point Brewing & Spirits in its proposed initial public offering and US$1.0 billion sale to Constellation Brands
• BIND Therapeutics in its initial public offering
• Cadence Pharmaceuticals in its US$1.4 billion sale to Mallinckrodt 
• Conatus Pharmaceuticals in its initial public offering, follow-on offerings, and in its reverse merger sale
• Crinetics Pharmaceuticals in venture financings, its initial public offering and in corporate governance matters
• DJO Incorporated in its US$1.6 billion sale to an affiliate of The Blackstone Group and acquisitions of Dr. Comfort and Elastic Therapy for US$300 million
• eFFECTOR Therapeutics in its venture financings with investors such as U.S. Venture Partners, Abingworth, Novartis Venture Funds, SR One, and Astellas Venture Management
• Elevation Pharmaceuticals in its venture financings with investors such as Canaan Partners, TPG Growth, Care Capital, and Novo Ventures, and in its sale to Sunovion for proceeds of up to US$430 million
• Erasca, a company dedicated to advancing exceptional scientific approaches to erase cancer, in formation structuring, venture financings with investors such as ARCH Venture Partners, Andreessen Horowitz, and Cormorant Asset Management, and in corporate governance matters
• Exagen in its bridge financings, initial public offering, and in corporate governance matters
• Evoke Pharma in venture financings, in its initial public offering, follow-on offerings, and in corporate governance matters
• Gossamer Bio in formation structuring, venture financings, its initial public offering and follow-on offerings, strategic acquisitions, and in corporate governance matters
• Level Studios, an integrated digital marketing and product development agency, in its sale to Rosetta
• Ligand Pharmaceuticals in strategic acquisitions, public company and corporate governance matters, and convert offering
• Meritage Pharma in venture financings with investors such as Domain Associates, Latterell Venture Partners, and The Vertical Group, and in its sale to ViroPharma Incorporated (with Shire as successor in interest) for up to US$240 million
• Oncternal Therapeutics in its reverse merger, public company representation, and follow-on offerings
• Phathom Pharmaceuticals in its initial public offering and in corporate governance matters
• Santarus in corporate governance matters, in its secondary public offering, and in its US$2.6 billion sale to Salix Pharmaceuticals
• Tealium, an innovative technology company that is a leader in real-time customer data management solutions, in venture financings and general company representation
• Zogenix in its venture financings, initial public offering and follow-on offerings, strategic acquisitions, and in corporate governance matters
• A number of investment banks in public offerings of equity securities for life sciences companies, including initial public offerings for AltheaDx, Ambit Biosciences, Cirius Therapeutics, Equillium, HTG Molecular, Horizon Pharma, Insys Therapeutics, Lumena Pharmaceuticals (prior to its sale), Poseida Therapeutics, Sophiris Bio, Synthorx, Tocagen, Tracon Pharma and Trius Therapeutics, as well as public offerings for Ardea, Arrowhead, Arena Pharmaceuticals, Biocryst, CareDx, Heron, Iovance, Mirati, Neurocrine, Optimer, Retrophin, Rigel, and Vical

Representative Speaking Engagements

• Speaker, “Getting to the Field - IPO Execution,” Marsh & McLennan IPO Bootcamp
• Speaker, “Your Company’s Next Step,” KPMG IPO Bootcamp
• Speaker, “Business Structure and Tax Strategies for Start-ups,” Association of Bioscience Financial Officers (ABFO) National Conference